drugset / Trial / NCT01698333

Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression

NCT01698333 ↗

Phase 2 Completed 25 enrolled Therapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

Adrenal suppression effects of corticosteroids are among the most important safety concerns for this group of products. This study is designed to determine the adrenal effects of the investigational formulation of 122-0551 and characterize the steady state pharmacokinetics of the formulation.

Timeline

Start
2012-04
Primary completion
2013-03
Completion
2013-07

Drugs

EvaluationDrugModalityDoseRoute
Subject 122-0551 Unknown — —

Indications